European Medicines Agency's Management Board Nominates Guido Rasi as New Executive Director
The European Medicines Agency's Management Board has nominated Guido Rasi on June 8,2011 as new Executive Director of the Agency. The Executive Director-designate has been invited to a hearing in front of the European Parliament Committee on Environment, Public Health and Food Safety on July 13, 2011. The Board will officially appoint the new Executive Director following his hearing and a positive response from the European Parliament.
Mr. Rasi has been Director-General of the Italian Medicines Agency since 2008, and member of the European Medicines Agency's Management Board since 2010.
Mr. Rasi holds a degree in medicine and surgery, with specialization in internal medicine, allergology, and clinical immunology from the University of Rome. From 1978 to 1990, Mr. Rasi worked as physician in hospital, research, and private practice. He worked from 1990 to 2008 in research at the Institute for Experimental Medicine of the National Research Council in Rome, directing the molecular medicine section from 2002 to 2005 and the Tor Vegata section from 2005 to 2008. He was made full professor of microbiology at the University of Rome (Tor Vegata) in 2008.
Andreas Pott will continue his role as Acting Executive Director until Guido Rasi takes office.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
